Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Nov 10;13(1):19605.
doi: 10.1038/s41598-023-45872-z.

Cannabis use and the risk of primary open-angle glaucoma: a Mendelian randomization study

Affiliations
Meta-Analysis

Cannabis use and the risk of primary open-angle glaucoma: a Mendelian randomization study

Andreas Katsimpris et al. Sci Rep. .

Abstract

Several observational studies have investigated the association between cannabis use and intraocular pressure, but its association with primary open-angle glaucoma (POAG) remains unclear. In this study, we leveraged human genetic data to assess through Mendelian randomization (MR) whether cannabis use affects POAG. We used five single-nucleotide polymorphisms (SNPs) associated with lifetime cannabis use (P-value < 5 × 10-8) from a genome-wide association study (GWAS) (N = 184,765) by the International Cannabis Consortium, 23andMe, and UK Biobank and eleven SNPs associated with cannabis use disorder (P-value < 5 × 10-7) from a GWAS meta-analysis of (17,068 cases and 357,219 controls of European descent) from Psychiatric Genomics Consortium Substance Use Disorders working group, Lundbeck Foundation Initiative for Integrative Psychiatric Research, and deCode. We associated the selected five SNPs from the GWAS of lifetime cannabis use and the eleven SNPs from the GWAS of cannabis use disorder, with the largest to date GWAS meta-analysis of POAG (16,677 cases and 199,580 controls). MR analysis suggested no evidence for a causal association of lifetime cannabis use and cannabis use disorder with POAG (odds ratio (OR) of outcome per doubling of the odds of exposure (95% confidence interval): 1.04 (0.88; 1.23) for lifetime cannabis use and 0.97 (0.92; 1.03) for cannabis use disorder). Sensitivity analyses to address pleiotropy and weak instrument bias yielded similar estimates to the primary analysis. In conclusion, our results do not support a causal association between cannabis use and POAG.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Mendelian randomization estimates for the effect of lifetime cannabis use on primary open-angle glaucoma. Estimates are reported as changes in odds of primary open-angle glaucoma per doubling in the prevalence of lifetime cannabis usea. aSNP single nucleotide polymorphism; CI confidence interval; MR-PRESSO Mendelian randomization pleiotropy residual sum and outlier; CAUSE causal analysis using summary effect estimates; BMI body mass index.
Figure 2
Figure 2
Mendelian randomization estimates for the effect of cannabis use disorder on primary open-angle glaucoma. Estimates are reported as changes in odds of primary open-angle glaucoma per doubling in the prevalence of cannabis use disordera. aSNP single nucleotide polymorphism; CI confidence interval; MR-PRESSO Mendelian randomization pleiotropy residual sum and outlier; CAUSE causal analysis using summary effect estimates; BMI body mass index.

References

    1. Tham YC, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090. doi: 10.1016/j.ophtha.2014.05.013. - DOI - PubMed
    1. Le A, Mukesh BN, McCarty CA, Taylor HR. Risk factors associated with the incidence of open-angle glaucoma: The visual impairment project. Invest. Ophthalmol. Vis. Sci. 2003;44:3783–3789. doi: 10.1167/iovs.03-0077. - DOI - PubMed
    1. Prum BE, Jr, et al. Primary open-angle glaucoma preferred practice pattern(®) guidelines. Ophthalmology. 2016;123:P41–p111. doi: 10.1016/j.ophtha.2015.10.053. - DOI - PubMed
    1. Beckers HJM, Schouten JSAG, Webers CAB, van der Valk R, Hendrikse F. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefe's Archiv. Clin. Exp. Ophthalmol. 2008;246:1485–1490. doi: 10.1007/s00417-008-0875-7. - DOI - PubMed
    1. Novack GD. Cannabinoids for treatment of glaucoma. Curr. Opin. Ophthalmol. 2016;27:146–150. doi: 10.1097/icu.0000000000000242. - DOI - PubMed

Publication types

MeSH terms